A phase II trial of Doxorubicin HCl Liposome Injection in patients with advanced pancreatic adenocarcinoma Journal Article

  


Authors: Schwartz, G. K.; Casper, E. S.
Article Title: A phase II trial of Doxorubicin HCl Liposome Injection in patients with advanced pancreatic adenocarcinoma
Abstract: We conducted a phase II study with doxorubicin encapsulated in a liposomal preparation (Doxorubicin HCl Liposome Injection) at a dose of 75 mg/m2 administered as a one hour infusion once every three weeks. Sixteen patients were entered to the trial and 15 are evaluable for response. Hematologic toxicity was significant. The median white blood count was 1.6×103/μl (range: 0.1–9.5), median absolute neutrophil count 0.6×103/μl (range: 0–5.8) and median platelet count was 142.0×103/μl (range: 20–327). Gastrointestinal toxicity was generally mild. Despite two minor responses in liver metastases with a significant decrease in CEA in one of these patients, no major responses were observed, excluding with 95% confidence, a response rate in excess of 20%. © 1995, Kluwer Academic Publishers. All rights reserved.
Keywords: adult; cancer chemotherapy; clinical article; aged; clinical trial; fatigue; neutropenia; doxorubicin; diarrhea; pancreatic neoplasms; antineoplastic agent; adenocarcinoma; phase 2 clinical trial; anemia; blood toxicity; leukopenia; nausea; stomatitis; thrombocytopenia; vomiting; carcinoembryonic antigen; gastrointestinal toxicity; liver metastasis; neutrophil; thrombocyte count; pancreas adenocarcinoma; pancreatic cancer; leukocyte count; infusions, intravenous; liposome; liposomes; encapsulation; intravenous drug administration; drug carriers; platelet count; middle age; anthracycline antibiotic agent; phase ii study; human; male; female; priority journal; article; support, u.s. gov't, p.h.s.; doxorubicin hcl liposome injection
Journal Title: Investigational New Drugs
Volume: 13
Issue: 1
ISSN: 0167-6997
Publisher: Springer  
Date Published: 1995-03-01
Start Page: 77
End Page: 82
Language: English
DOI: 10.1007/bf02614225
PUBMED: 7499113
PROVIDER: scopus
DOI/URL:

https://www.scopus.com/inward/record.uri?eid=2-s2.0-0029152029&doi=10.1007%2fBF02614225&partnerID=40&md5=a1b09efdd3f6f2ae0f410b50d04ec7b2
Notes: Article -- Export Date: 28 August 2018 -- Source: Scopus
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Gary Schwartz
    385 Schwartz
  2. Ephraim S Casper
    108 Casper
Related MSK Work